ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

LPCN Lipocine Inc

4.7983
0.2483 (5.46%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Lipocine Inc LPCN 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.2483 5.46% 4.7983 13:00:00
개장가 저가 고가 종가 전일 종가
4.52 4.38 4.8099 4.7977 4.55
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
11/04/202420:00PRNUSLipocine Announces Positive LPCN 2401 Clinical Results..
28/03/202421:00PRNUSLipocine Announces Positive Week 52 Results from LPCN 1148..
25/03/202421:00PRNUSLipocine Announces First Cohort Dosed in Pivotal Study of..
08/03/202407:31EDGAR2Form 8-K - Current report
07/03/202422:00PRNUSLipocine Announces Financial Results for the Full Year Ended..
07/03/202420:08EDGAR2Form 8-K - Current report
07/03/202420:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/03/202422:00PRNUSLipocine to Present at 36th Annual Roth Conference
06/03/202420:01EDGAR2Form 8-K - Current report
13/02/202406:10EDGAR2Form 8-K - Current report
06/02/202422:00PRNUSLipocine Announces Confirmation of Dosing Regimen for..
02/02/202422:00PRNUSLipocine Announces Continued Commercialization of TLANDO®..
18/01/202422:20EDGAR2Form 8-K - Current report
18/01/202422:00PRNUSLipocine and Verity Pharma Enter into License Agreement for..
20/12/202300:00EDGAR2Form 8-K - Current report
19/12/202322:00PRNUSLipocine to Present at Biotech Showcase 2024
23/11/202306:15EDGAR2Form S-3 - Registration statement under Securities Act of..
14/11/202304:45EDGAR2Form 8-K - Current report
14/11/202304:45PRNUSLipocine Releases Late Breaking Presentation on LPCN 1148..
09/11/202303:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202323:50EDGAR2Form 8-K - Current report
08/11/202322:00PRNUSLipocine Announces Financial Results for the Third Quarter..
01/11/202322:31EDGAR2Form 8-K - Current report
01/11/202321:00PRNUSLipocine to Present Clinical Data on LPCN 1148 at The Liver..
26/10/202322:35EDGAR2Form 8-K - Current report
26/10/202321:00PRNUSLipocine Completes Successful Meeting with FDA on LPCN 1154..
24/10/202308:00PRNUSLipocine to Present at the H.C. Wainwright Annual NASH..
07/10/202305:05EDGAR2Form 8-K - Current report
20/09/202305:10EDGAR2Form 8-K - Current report
20/09/202305:05PRNUSLipocine to Present at the Cantor Fitzgerald Global..
10/08/202321:35EDGAR2Form 8-K - Current report
10/08/202321:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/08/202321:00PRNUSLipocine Announces Financial Results for the Second Quarter..
27/07/202319:45EDGAR2Form 8-K - Current report
27/07/202319:30PRNUSLPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients..
14/06/202321:00PRNUSLipocine to Present at H.C. Wainwright Annual..
07/06/202321:00PRNUSLipocine to Present LPCN 1148 and LPCN 1144 at the EASL..
16/05/202320:00PRNUSPositive Topline Clinical Results Support Streamlined..
11/05/202319:00PRNUSLipocine Announces Financial Results for the First Quarter..

최근 히스토리

Delayed Upgrade Clock